OBJECTIVE: To characterize the pharmacokinetics of combinations of dexmedetomidine, vatinoxan and ketamine in cats. STUDY DESIGN: Partially randomized, crossover, experimental study. ANIMALS: A group of six healthy male neutered cats, aged 1-2 years, weighing 5.4 ± 0.3 kg. METHODS: Each cat was administered six treatments: dexmedetomidine (25 μg kg RESULTS: Two-compartment models best fitted the time-plasma dexmedetomidine, vatinoxan and ketamine concentrations. The models predicted that vatinoxan increases the clearance of dexmedetomidine and decreases the bioavailability of IM ketamine and that increasing doses of ketamine increase the volume of the central compartment for dexmedetomidine and the bioavailability of IM ketamine. The volume of distribution at steady state (mL kg CONCLUSIONS AND CLINICAL RELEVANCE: The pharmacokinetics of dexmedetomidine and the bioavailability of ketamine were affected by vatinoxan and the dose of ketamine.